RecruitingNot ApplicableNCT05898074

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

Novel Application of RADA16 Hydrogel in Reducing Sinonasal Morbidity After Endoscopic Skull Base Surgery


Sponsor

Indiana University

Enrollment

30 participants

Start Date

Oct 9, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Non-Absorbable Packing (Silastic Splint) and a medical device called PuraGel (RADA16) Hydrogel for people with cerebrospinal fluid leakage, nasal; hypertrophy, mucous membrane (septum), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENon-Absorbable Packing (Silastic Splint)

Participant will have silastic splint applied to nasoseptal flap harvest site

DEVICEPuraGel (RADA16) Hydrogel

Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site


Locations(1)

Indiana University

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05898074


Related Trials